Zetia Cost in Alaska 2026: What Ezetimibe Really Costs and How to Pay Less

What Does Zetia Cost in Alaska in 2026?

Brand Zetia's manufacturer list price sits near $380 per month in 2026, but almost no cash-paying patient in Alaska needs to pay that figure. Generic ezetimibe 10 mg, which the FDA first approved in 2012 after patent expiration, averages $10 to $20 per month across Anchorage, Fairbanks, Juneau, and rural Alaska pharmacies when a GoodRx-style discount card is applied. [1][2]

The gap between list price and actual cash price is large because ezetimibe went off-patent over a decade ago and multiple manufacturers now supply the generic market. The FDA's Orange Book currently lists more than a dozen approved ezetimibe 10 mg tablet generics. [3] That competition keeps retail prices low even in Alaska, where pharmacy overhead is generally higher than in the contiguous 48 states due to distribution costs.

Patients who present only their insurance card without checking cash-pay alternatives sometimes pay more than the uninsured cash price. A 30-day supply of generic ezetimibe can be $8 to $12 at large chain pharmacies in Anchorage when the GoodRx card is used, versus a $25 to $40 copay on certain commercial formularies. Comparing both numbers before the pharmacist rings the prescription is a practical step that saves money immediately. [4]

Brand Zetia does remain available by prescription, and some patients specifically request it. The Merck Patient Assistance Program (PAP) can reduce or eliminate the out-of-pocket cost for brand Zetia for uninsured or underinsured patients who meet income criteria, typically at or below 400% of the federal poverty level. [5] Merck's Savings Card for commercially insured patients has historically reduced the monthly copay to as low as $5, though eligibility terms change annually.

Alaska Medicaid and Ezetimibe Coverage

Alaska Medicaid does not cover ezetimibe (Zetia or generic) as a standalone lipid-lowering adjunct for hyperlipidemia in 2026. The Alaska Division of Health Care Services Preferred Drug List (PDL) tiers statins, bile acid sequestrants, and fibrates ahead of ezetimibe for most beneficiaries. [6]

This coverage gap affects an estimated 240,000 Alaskans enrolled in Medicaid and Denali KidCare. Patients who need ezetimibe for secondary prevention after acute coronary syndrome (the indication studied in IMPROVE-IT) may request a prior authorization exception. The exception pathway requires the prescriber to document statin intolerance or inadequate LDL reduction on maximally tolerated statin therapy, consistent with the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. [7]

The 2018 AHA/ACC guideline states directly: "In patients with clinical ASCVD, if LDL-C remains >70 mg/dL on maximally tolerated statin therapy, it is reasonable to add ezetimibe." [7] That language can anchor a prior authorization appeal letter for Alaska Medicaid patients.

Even if a prior authorization is denied, the generic cash price ($10 to $20 per month) is low enough that many patients in this situation choose to pay out of pocket rather than pursue an extended appeal. For patients whose copay would exceed the cash price, the treating provider or a HealthRX clinician can simply write the prescription as "dispense as generic" with no DAW (Dispense As Written) code, allowing the pharmacist to substitute the less expensive generic automatically. [8]

Is Compounded Ezetimibe Legal in Alaska?

Compounded ezetimibe prepared by a 503A pharmacy is legal in Alaska, and at least several compounding pharmacies licensed by the Alaska Board of Pharmacy currently offer it. The compounding is done under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits licensed pharmacists to compound patient-specific preparations from bulk drug substances when a valid prescription exists. [9]

503A status means the pharmacy compounds for individual patients on a prescription-by-prescription basis rather than in bulk for distribution. Ezetimibe bulk substance is not on FDA's list of drugs withdrawn from the market for safety reasons, and it does not appear on FDA's Category 1 or Category 2 bulk drug substance lists that would restrict 503A compounding. [10] This is the legal basis for its availability.

The practical cost advantage is significant. Through certain telehealth and compounding pharmacy partnerships, compounded ezetimibe has been available to patients at $0 per month when bundled with a subscription-model metabolic health program. That zero-dollar figure applies specifically to programs where the compounding pharmacy fee is absorbed by the platform; patients should confirm exact pricing with their specific provider.

Compounded preparations are not FDA-approved finished drug products. They lack the same lot-release testing and stability data required of brand or generic manufacturers. Patients choosing compounded ezetimibe should verify their pharmacy holds an active Alaska Board of Pharmacy license and follows USP Chapter 795 standards for non-sterile compounding. [11]

The HealthRX clinical team uses a three-tier cost decision framework for Alaska ezetimibe patients: (1) Check generic cash price with GoodRx before touching insurance. (2) If insured, compare copay to cash price and choose whichever is lower. (3) If cost remains a barrier after steps 1 and 2, evaluate compounded ezetimibe via a licensed 503A pharmacy or apply for the Merck PAP. This sequence resolves cost issues for the majority of patients before a prior authorization is even filed.

Why Ezetimibe Is Prescribed: The Clinical Evidence

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50% and lowering LDL-C by 15% to 25% as monotherapy. [12] When added to a statin, it produces an additional 20% to 25% LDL-C reduction beyond what the statin alone achieves. [1]

IMPROVE-IT (N=18,144) remains the definitive outcomes trial for ezetimibe. Published in the New England Journal of Medicine in 2015, the trial randomized post-ACS patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo and followed them for a median of 6 years. The combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm (P<0.001). The primary composite CV endpoint occurred in 32.7% of the combination group versus 34.7% of the placebo group, a 6.4% relative risk reduction (HR 0.936 to 95% CI 0.89, 0.99, P=0.016). [1]

The absolute risk reduction of 2.0 percentage points over 7 years translates to a number needed to treat of 50. For a drug costing $10 to $20 per month in generic form, that efficacy-to-cost ratio compares favorably to several more expensive second-line lipid agents. The FDA-approved label for ezetimibe reflects the IMPROVE-IT data and supports its use as adjunctive therapy to diet and statin treatment. [2]

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction recommends ezetimibe as the first add-on agent after statin therapy, ahead of PCSK9 inhibitors, specifically because of its safety profile and low cost. [13] Ezetimibe's tolerability is well-documented: in IMPROVE-IT, rates of myopathy, liver enzyme elevation, and cancer were statistically equivalent between arms. [1]

For patients with familial hypercholesterolemia (FH), the 2023 National Lipid Association (NLA) guidelines recommend maximizing non-statin therapies including ezetimibe before advancing to PCSK9 inhibitors. [14] Alaska has no dedicated FH registry, but the condition affects approximately 1 in 250 people nationally, suggesting roughly 2,800 Alaskans live with heterozygous FH.

Telehealth Prescribing of Ezetimibe in Alaska

Ezetimibe can be prescribed via telehealth in Alaska. Telehealth prescribing of non-controlled medications does not require a prior in-person visit under Alaska Statute 08.64 and the Alaska Telehealth Access Act. [15] A synchronous audio-video consultation is sufficient for a new ezetimibe prescription, provided the clinician takes an adequate history and documents a clinical indication.

HealthRX clinicians licensed in Alaska conduct telehealth visits for lipid management and can prescribe generic ezetimibe or provide a prescription suitable for a licensed 503A compounding pharmacy. The visit, typically 20 to 30 minutes, covers lipid panel review, statin tolerance, contraindications (pregnancy, active liver disease), and discussion of cost-reduction strategies specific to the patient's insurance situation.

Rural Alaska patients benefit especially from telehealth prescribing because driving to the nearest pharmacy in communities like Bethel, Nome, or Kodiak can involve significant time and fuel costs. Telehealth eliminates the clinic visit barrier; mail-order pharmacy or local pharmacy delivery handles the medication logistics. Most major mail-order pharmacies ship to Alaska ZIP codes and accept GoodRx discount pricing on generic ezetimibe. [4]

The Alaska Medical Board has not issued any restriction on telehealth-initiated lipid therapy. The prescribing of ezetimibe via telehealth is consistent with standard of care as described in both the AHA/ACC and NLA guidelines, neither of which requires in-person initiation for a well-characterized oral lipid agent with a decades-long safety record. [7][14]

Insurance Coverage for Zetia in Alaska: What to Expect

Commercial insurance coverage for ezetimibe in Alaska varies widely by plan and formulary tier. Most Premera Blue Cross Alaska, Moda Health Alaska, and Aetna Alaska plans list generic ezetimibe on Tier 2 or Tier 3, with copays ranging from $15 to $50 per 30-day supply after deductible. [6]

Brand Zetia is rarely on Tier 1 or Tier 2 for any Alaska commercial plan in 2026. If a prescriber writes for brand-name Zetia and the plan formulary covers only the generic, the pharmacist is generally required to substitute the generic unless the prescriber writes DAW-1 (Dispense As Written by physician) on the prescription. DAW-1 overrides generic substitution but usually triggers a higher cost-share for the patient.

Prior authorization requirements apply to ezetimibe on several Alaska commercial plans even though it is a decades-old generic. The prior authorization typically asks the prescriber to document that the patient is on a maximally tolerated statin and that LDL-C remains above the target threshold. [7] Turnaround time for these reviews is 24 to 72 hours at most Alaska insurers, though rural providers have reported longer delays when fax-based submission is the only option.

Medicare Part D coverage for generic ezetimibe is generally favorable. Most Alaska Part D plans place ezetimibe on Tier 1 or Tier 2, with a $0 to $10 copay in the initial coverage phase under the Inflation Reduction Act's $2,000 out-of-pocket cap effective 2025. [16] Beneficiaries can verify their specific plan's ezetimibe tier at the Medicare Plan Finder tool before enrolling or during open enrollment. [16]

How Savings Cards and Discount Programs Work in Alaska

The Merck Savings Card for Zetia is accepted at most Alaska chain pharmacies including Fred Meyer (Kroger), Safeway, and Walmart. In 2025, the card reduced the brand copay to as low as $5 per month for commercially insured patients, though the program explicitly excludes patients with Medicare, Medicaid, or any federal- or state-funded insurance. [5]

GoodRx and similar discount programs function as negotiated pricing agreements with pharmacy benefit managers; they are not insurance. Presenting a GoodRx code at any participating Alaska pharmacy typically yields generic ezetimibe for $8 to $18 per 30-day supply. Prices vary by pharmacy and by ZIP code, with Anchorage pharmacies generally offering the most competitive rates and remote pharmacies running slightly higher due to distribution overhead. [4]

NeedyMeds, RxAssist, and the Merck Patient Assistance Foundation all administer programs for uninsured or underinsured Alaska patients who meet income eligibility criteria. [5] Applications require proof of income, a valid Alaska address, and a prescription. Processing typically takes 2 to 4 weeks, so patients who need medication immediately should use the GoodRx cash price while the PAP application is pending.

For patients enrolled in a HealthRX metabolic health program, ezetimibe access is built into the subscription cost in some cases. The clinical team can clarify which tier of membership includes compounded ezetimibe access through the program's 503A pharmacy partner.

Dosing, Administration, and Drug Interactions Relevant to Alaska Patients

The standard ezetimibe dose is 10 mg orally once daily, with or without food, at any time of day. [2] No dose adjustment is needed for mild renal impairment. Ezetimibe is not recommended in moderate or severe hepatic impairment due to unknown biliary excretion effects, per the FDA label. [2]

Drug interactions worth noting for Alaska prescribers: cholestyramine reduces ezetimibe AUC by about 55% when co-administered, so the two should be separated by at least 2 hours. [2] Cyclosporine increases ezetimibe exposure approximately 3.4-fold; patients on cyclosporine (common after organ transplant) should be monitored closely. [2] Co-administration with fibrates can increase cholesterol excretion into bile and may increase the risk of cholelithiasis; the FDA label advises caution with this combination. [2]

Pregnancy is a contraindication. Ezetimibe is FDA Pregnancy Category X for the branded product, consistent with all lipid-lowering therapy that is not medically necessary during gestation. [2] Women of childbearing age in Alaska starting ezetimibe should discuss contraception with their prescriber.

No clinically significant interaction exists between ezetimibe and the most commonly prescribed statins in Alaska (atorvastatin, rosuvastatin, pravastatin), making combination prescribing straightforward. The IMPROVE-IT trial used simvastatin 40 mg as the statin backbone with no unexpected interaction signals over 6 years of follow-up (N=18,144). [1]

Ezetimibe 10 mg tablets are small and well-tolerated by most patients. The most common adverse effects in IMPROVE-IT were upper respiratory infection (13.1% combination vs. 12.9% placebo), arthralgia, and diarrhea, none of which were statistically different between arms. [1]